X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
https://www.prnewswire.com/news-releases/alkermes-presents-analyses-from-long-term-safety-study-of-lybalvi-olanzapine-and-samidorphan-at-2024-congress-of-the-schizophrenia-international-research-society-302109802.html
https://www.prnewswire.com/news-releases/alkermes-announces-topline-results-from-long-term-open-label-safety-and-durability-of-treatment-effect-study-of-lybalvi-olanzapine-and-samidorphan-302024987.html
https://www.prnewswire.com/news-releases/journal-of-clinical-psychiatry-publishes-data-from-alkermes-enlighten-early-study-of-lybalvi-olanzapine-and-samidorphan-in-young-adults-early-in-their-illness-301779348.html
https://www.indianpharmapost.com/news/zydus-receives-final-approval-from-the-usfda-for-olanzapine-13855
https://www.pharmaexcipients.com/news/amorphization-olanzapine-pellets/
https://www.biospace.com/article/awakn-life-sciences-signs-drug-development-agreement-with-catalent-for-zydis-r-technology-an-orally-disintegrating-tablet-to-conduct-feasibility-studies-to-improve-differentiation-of-its-mdma-program/?s=100
https://www.fiercepharma.com/marketing/alkermes-lybalvi-a-new-litmus-test-for-mental-illness-marketing
https://www.prnewswire.com/news-releases/alkermes-announces-positive-topline-results-from-enlighten-early-phase-3b-study-of-lybalvi-in-patients-early-in-illness-301477193.html
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-august-18-2021-1629274448.pdf
https://www.reuters.com/business/healthcare-pharmaceuticals/alkermes-schizophrenia-drug-gets-us-fda-nod-2021-06-01/
https://www.prnewswire.com/news-releases/fda-accepts-alkermes-resubmission-of-new-drug-application-for-alks-3831-301198736.html
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-november-11-2020-1605074117.pdf
https://www.clinicaltrialsarena.com/comment/alkermes-schizophrenia-bipolar-disorder-candidate-fda-adcom-phase-iii-weight-gain-data/
https://www.moneycontrol.com/news/business/indoco-remedies-gets-usfda-nod-for-schizophrenia-bipolar-disorder-treatment-drug-5653621.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206155
https://www.prnewswire.com/news-releases/impel-neuropharma-announces-publication-of-positive-results-of-snap-101-study-for-inp105-for-the-treatment-of-acute-agitation-in-the-journal-of-clinical-psychiatry-301086100.html
https://www.prnewswire.com/news-releases/impel-neuropharma-announces-publication-of-positive-results-of-snap-101-study-for-inp105-for-the-treatment-of-acute-agitation-in-the-journal-of-clinical-psychiatry-301086100.html
https://www.prnewswire.com/news-releases/journal-of-clinical-psychiatry-publishes-data-from-alkermes-phase-3-enlighten-1-efficacy-study-of-alks-3831-in-patients-with-schizophrenia-301015875.html
http://www.pmlive.com/pharma_news/ema_begins_review_of_kites_car-t_for_mantle_cell_lymphoma_1323675
https://endpts.com/sanofi-regeneron-dupixent-alkermes-antipsychotic-get-dates-with-the-fda-concert-wins-reprieve-in-incyte-patent-fight/
https://www.fiercebiotech.com/biotech/jpm-conversation-steve-paul-ceo-karuna-therapeutics
https://www.catalent.com/catalent-news/catalent-to-partner-with-ethicann-on-new-fast-dissolve-cannabinoid-based-treatment-for-multiple-sclerosis-spasticity/
https://www.contractpharma.com/contents/view_breaking-news/2019-10-31/cycle-catalent-to-develop-formulations-targeting-rare-disorders/
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/chinese-growth-shots-some-years-away-for-pharma-companies/articleshow/71513734.cms
https://endpts.com/hansoh-grabs-1b-windfall-in-the-latest-china-pharma-ipo-to-hit-the-hong-kong-exchange/
https://www.reuters.com/article/us-alkermes-study/alkermes-says-long-acting-drugs-could-help-schizophrenics-stay-on-medication-longer-idUSKCN1RL19O
https://www.reuters.com/article/us-johnson-johnson-fda/johnson-johnsons-nasal-spray-for-depression-wins-fda-panel-backing-idUSKCN1Q12G5
https://seekingalpha.com/article/4226783-alkermes-looks-fda-approval-schizophrenia-drug
https://xconomy.com/boston/2018/11/29/alkermes-schizophrenia-drug-heads-to-fda-but-questions-linger/
https://www.reuters.com/article/us-alkermes-study/alkermes-schizophrenia-drug-keeps-weight-gain-side-effect-in-check-idUSKCN1NY1I4
https://www.fiercepharma.com/marketing/philly-cracks-down-pharma-sales-reps-looks-to-force-registration-and-ban-gifts
https://www.fiercepharma.com/marketing/philly-cracks-down-pharma-sales-reps-looks-to-force-registration-and-ban-gifts
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206238
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209399
https://www.in-pharmatechnologist.com/Article/2018/09/04/Intranasal-antipsychotic-Ph-I-study-begins-with-first-participant-dosed
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=090459
https://www.thehindubusinessline.com/companies/zydus-cadila-gets-usfda-nod-to-market-4-generic-products/article24450730.ece
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208146
http://phx.corporate-ir.net/phoenix.zhtml?c=92211&p=irol-corporateNewsArticle&ID=2346885
https://www.statnews.com/2017/08/16/eli-lilly-canada-patents-zyprexa-strattera/
http://www.fiercebiotech.com/biotech/alkermes-says-it-s-advancing-full-steam-schizophrenia-candidate
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204866
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-may-17-2017-1494997195.pdf
http://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/dr-reddys-aurobindo-recall-drugs-from-us-market/articleshow/57165745.cms
http://www.biospace.com/News/new-fda-report-cites-22-drugs-that-passed-phase-ii/444652/source=TopBreaking?intcid=homepage-seekernewssection-tabtopbreakingnews
Market Place
Share 
